- Title: Title: Serum Ceramide Species and Meteorin-Like Protein as a Novel Combined Biomarker Panel for the Diagnosis of Early-Stage Type 2 Diabetes Mellitus

Novel Combined Biomarker Panel for the Diagnosis of Early-Stage Type 2 Diabetes Mellitus

  • Xiaoyu Zhao School of Medicine, Xuchang University, Xuchang,Henan , 461000, China
  • Muhriddin Pulatov 2. Department of Medicine, Termez University of Economics and Service, Termez, Uzbekistan,
  • Shakhlokhon Kurbanova 3. Department of Psychology and medicine, Mamun University. Khiva, Uzbekistan.
DOI: https://doi.org/10.5937/jomb0-63198
Keywords: Type 2 Diabetes Mellitus; Biomarkers; Ceramides; Sphingolipids; Meteorin-like protein; Insulin Resistance; Lipotoxicity.

Abstract


Background: The identification of biomarkers reflecting early pathophysiological changes in Type 2 Diabetes Mellitus (T2DM) is crucial for timely intervention. Ceramides, lipotoxic sphingolipids, and Meteorin-like protein (Metrnl), an insulin-sensitizing adipomyokine, are mechanistically linked to T2DM development.
Aims: To compare serum levels of specific ceramides (Cer-16, Cer-18, Cer-24, Cer-24:1) and Metrnl between T2DM patients and controls, and to evaluate their individual and combined diagnostic accuracy.
Methods: This case-control study included 80 newly diagnosed T2DM patients and 80 age- and BMI-matched normoglycemic controls. Fasting serum was analysed for standard biochemical parameters. Ceramide species were quantified by LC-MS/MS. Serum Metrnl was measured via ELISA.
Results: The T2DM group exhibited significantly elevated levels of Cer-16 (p<0.001) and Cer-18 (p<0.01), and reduced levels of Cer-24 and Metrnl (both p<0.001). The Cer-16/Cer-24 ratio was significantly higher in T2DM. Strong correlations were found between these biomarkers and HOMA-IR/HbA1c. A multivariate logistic regression model combining Cer-16, Cer-24, and Metrnl yielded an AUC of 0.93 for T2DM discrimination, superior to any single marker.
Conclusions: A distinct ceramide profile (high Cer-16, low Cer-24) coupled with low Metrnl characterizes early T2DM. Their combination forms a synergistic biomarker panel with high diagnostic potential, mirroring the dual pathology of lipotoxicity and impaired metabolic protection.

References

1. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2023. Diabetes Care 2023;46(Suppl 1):S19-S40.
2. Srikanthan K, Shapiro JI, Sodhi K. The role of ceramides in diabetes and cardiovascular disease regulation of ceramides by adipokines. Front Endocrinol (Lausanne) 2020;11:569250.
3. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev 2018;98(4):2133-223.
4. Raichur S, Wang ST, Chan PW, et al. CerS2 haploinsufficiency inhibits β-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell Metab 2014;20(4):687-95.
5. Turpin-Nolan SM, Brüning JC. The role of ceramides in metabolic disorders: when size and localization matters. Nat Rev Endocrinol 2020;16(4):224-33.
6. Park JW, Park WJ, Kuperman Y, et al. Ceramide synthase 2 deficiency aggravates AOM-DSS-induced colitis in mice: role of colon barrier integrity. Cell Mol Gastroenterol Hepatol 2017;4(1):63-81.
7. Lemaitre RN, Yu C, Hoofnagle A, et al. Circulating sphingolipids, insulin, HOMA-IR, and HOMA-B: The Strong Heart Family Study. Diabetes 2018;67(8):1663-72.
8. Scheja L, Heeren J. The endocrine function of adipose tissues in health and cardiometabolic disease. Nat Rev Endocrinol 2019;15(9):507-24.
9. Rao RR, Long JZ, White JP, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell 2014;157(6):1279-91.
10. Jung TW, Lee SH, Kim HC, et al. METRNL attenuates lipid-induced inflammation and insulin resistance via AMPK or PPARδ-dependent pathways in skeletal muscle of mice. Exp Mol Med 2018;50(9):1-11.
11. Wang K, Li F, Wang C, et al. Serum levels of Meteorin-like protein (Metrnl) are associated with the presence and severity of coronary artery disease. Tohoku J Exp Med 2019;247(3):173-81.
12. Li Z, Wang G, Zhu YJ, et al. The relationship between circulating Metrnl levels and type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Res Clin Pract 2021;173:108687.
13. El-Ashmawy HM, Selim FO, Hosny TA, et al. Association of low serum Metrnl concentrations with hyperglycemia and dyslipidemia in type 2 diabetic patients. Diabetes Metab Syndr 2021;15(1):17-22.
14. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32(7):1327-34.
15. Kasumov T, Li L, Li M, et al. Ceramide as a mediator of non-alcoholic fatty liver disease and associated atherosclerosis. PLoS One 2015;10(5):e0126910.
16. Stratford S, Hoehn KL, Liu F, et al. Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J Biol Chem 2004;279(35):36608-15.
17. Holland WL, Brozinick JT, Wang LP, et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 2007;5(3):167-79.
18. Grosch S, Schiffmann S, Geisslinger G. Chain length-specific properties of ceramides. Prog Lipid Res 2012;51(1):50-62.
19. Laaksonen R, Ekroos K, Sysi-Aho M, et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J 2016;37(25):1967-76.
20. Lee JH, Kang YE, Chang JY, et al. An engineered Meteorin-like molecule with increased receptor binding affinity improves glucose metabolism in obese mice. J Biol Chem 2020;295(25):8569-81.
21. Lee JO, Byun WS, Kang MJ, et al. The myokine meteorin-like (Metrnl) improves glucose tolerance in both skeletal muscle cells and mice by targeting AMPKα2. FEBS J 2020;287(10):2087-104.
22. Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, et al. Metrnl and irisin: new adipokines as therapeutic targets in metabolic dysregulation. Endocr Metab Immune Disord Drug Targets 2022;22(13):1277-87.
23. Meikle PJ, Summers SA. Sphingolipids and phospholipids in insulin resistance and related metabolic disorders. Nat Rev Endocrinol 2017;13(2):79-91.
24. Sokolowska E, Blachnio-Zabielska. The role of ceramides in insulin resistance. Front Endocrinol (Lausanne) 2019;10:577.
25. Guasch-Ferré M, Hruby A, Toledo E, et al. Metabolomics in prediabetes and diabetes: a systematic review and meta-analysis. Diabetes Care 2016;39(5):833-46.
26. Ottosson F, Smith E, Melander O, et al. Altered asparagine and glutamate homeostasis precede coronary artery disease and type 2 diabetes. J Clin Endocrinol Metab 2018;103(8):3060-9.
27. Wigger L, Cruciani-Guglielmacci C, Nicolas A, et al. Plasma Dihydroceramides Are Diabetes Susceptibility Biomarker Candidates in Mice and Humans. Cell Rep 2017;18(9):2269-79.
28. Bluher M. Metabolically healthy obesity. Endocr Rev 2020;41(3):bnaa004.
29. Chew WS, Torta F, Ji S, et al. Large-scale lipidomics identifies associations between plasma sphingolipids and T2DM incidence. JCI Insight 2019;5(13):e126925.
Published
2026/05/11
Issue
Ahead of print
Section
Original paper

Copyright (c) 2026 Xiaoyu Zhao , Muhriddin Pulatov , Shakhlokhon Kurbanova

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.